86 related articles for article (PubMed ID: 12765423)
1. N-acetylcysteine reduces the risk of re-hospitalisation among patients with chronic obstructive pulmonary disease.
Gerrits CM; Herings RM; Leufkens HG; Lammers JW
Eur Respir J; 2003 May; 21(5):795-8. PubMed ID: 12765423
[TBL] [Abstract][Full Text] [Related]
2. Letter to the Editor on: Intravenous N-acetylcysteine in respiratory disease with abnormal mucus secretion.
Adeli SH; Jazi K
Eur Rev Med Pharmacol Sci; 2024 Apr; 28(8):2986-2987. PubMed ID: 38708454
[No Abstract] [Full Text] [Related]
3. N -acetylcysteine for Trichotemnomania in an Adult Female With Williams Syndrome.
Carroll HM; McDougle CJ; Thom RP
J Clin Psychopharmacol; 2024 May-Jun 01; 44(3):321-323. PubMed ID: 38497565
[No Abstract] [Full Text] [Related]
4. Influence of N-acetylcysteine on chronic bronchitis or COPD exacerbations: a meta-analysis.
Cazzola M; Calzetta L; Page C; Jardim J; Chuchalin AG; Rogliani P; Matera MG
Eur Respir Rev; 2015 Sep; 24(137):451-61. PubMed ID: 26324807
[TBL] [Abstract][Full Text] [Related]
5. Oral acetylcysteine reduces exacerbation rate in chronic bronchitis: report of a trial organized by the Swedish Society for Pulmonary Diseases.
Boman G; Bäcker U; Larsson S; Melander B; Wåhlander L
Eur J Respir Dis; 1983 Aug; 64(6):405-15. PubMed ID: 6350033
[TBL] [Abstract][Full Text] [Related]
6. High-dose N-acetylcysteine in stable COPD: the 1-year, double-blind, randomized, placebo-controlled HIACE study.
Tse HN; Raiteri L; Wong KY; Yee KS; Ng LY; Wai KY; Loo CK; Chan MH
Chest; 2013 Jul; 144(1):106-118. PubMed ID: 23348146
[TBL] [Abstract][Full Text] [Related]
7. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial.
Decramer M; Rutten-van Mölken M; Dekhuijzen PN; Troosters T; van Herwaarden C; Pellegrino R; van Schayck CP; Olivieri D; Del Donno M; De Backer W; Lankhorst I; Ardia A
Lancet; 2005 Apr 30-May 6; 365(9470):1552-60. PubMed ID: 15866309
[TBL] [Abstract][Full Text] [Related]
8. Twice daily N-acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double-blind placebo-controlled trial.
Zheng JP; Wen FQ; Bai CX; Wan HY; Kang J; Chen P; Yao WZ; Ma LJ; Li X; Raiteri L; Sardina M; Gao Y; Wang BS; Zhong NS;
Lancet Respir Med; 2014 Mar; 2(3):187-94. PubMed ID: 24621680
[TBL] [Abstract][Full Text] [Related]
9. N-acetylcysteine in patients with COPD exacerbations associated with increased sputum.
Ayfer Aytemur Z; Baysak A; Ozdemir O; Köse T; Sayiner A
Wien Klin Wochenschr; 2015 Apr; 127(7-8):256-61. PubMed ID: 25595117
[TBL] [Abstract][Full Text] [Related]
10. Benefits of high-dose N-acetylcysteine to exacerbation-prone patients with COPD.
Tse HN; Raiteri L; Wong KY; Ng LY; Yee KS; Tseng CZS
Chest; 2014 Sep; 146(3):611-623. PubMed ID: 24833327
[TBL] [Abstract][Full Text] [Related]
11. N-acetylcysteine for COPD: the evidence remains inconclusive--authors' reply.
Zheng JP; Zhong NS
Lancet Respir Med; 2014 Apr; 2(4):e3-4. PubMed ID: 24717632
[No Abstract] [Full Text] [Related]
12. N-acetylcysteine for COPD: the evidence remains inconclusive.
Turner RD; Bothamley GH
Lancet Respir Med; 2014 Apr; 2(4):e3. PubMed ID: 24717631
[No Abstract] [Full Text] [Related]
13. N-acetylcysteine in COPD may be beneficial, but for whom?
Cazzola M; Matera MG
Lancet Respir Med; 2014 Mar; 2(3):166-7. PubMed ID: 24621673
[No Abstract] [Full Text] [Related]
14. Effect of high/low dose N-acetylcysteine on chronic obstructive pulmonary disease: a systematic review and meta-analysis.
Shen Y; Cai W; Lei S; Zhang Z
COPD; 2014 Jun; 11(3):351-8. PubMed ID: 24378052
[TBL] [Abstract][Full Text] [Related]
15. [N-acetylcysteine reduces exacerbation frequency in COPD].
Markun S
Praxis (Bern 1994); 2013 Nov; 102(24):1495-6. PubMed ID: 24280608
[No Abstract] [Full Text] [Related]
16. The role for N-acetylcysteine in the management of COPD.
Dekhuijzen PN; van Beurden WJ
Int J Chron Obstruct Pulmon Dis; 2006; 1(2):99-106. PubMed ID: 18046886
[TBL] [Abstract][Full Text] [Related]
17. Role of N-acetylcysteine in the management of COPD.
Sadowska AM; Verbraecken J; Darquennes K; De Backer WA
Int J Chron Obstruct Pulmon Dis; 2006; 1(4):425-34. PubMed ID: 18044098
[TBL] [Abstract][Full Text] [Related]
18. High-dose N-acetylcysteine in patients with exacerbations of chronic obstructive pulmonary disease.
Zuin R; Palamidese A; Negrin R; Catozzo L; Scarda A; Balbinot M
Clin Drug Investig; 2005; 25(6):401-8. PubMed ID: 17532680
[TBL] [Abstract][Full Text] [Related]
19. N-acetylcysteine and exacerbations of chronic obstructive pulmonary disease.
Sutherland ER; Crapo JD; Bowler RP
COPD; 2006 Dec; 3(4):195-202. PubMed ID: 17361500
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
